Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.

Item

http://www.wikidata.org/entity/Q34522003

Q34522003

about

Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial How Grim is Pancreatic Cancer?Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles Systemic treatment for inoperable pancreatic adenocarcinoma: review and update Gatifloxacin induces S and G2-phase cell cycle arrest in pancreatic cancer cells via p21/p27/p53 Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis Clinical Translation of Nanomedicine.A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer.Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.Meta-analysis of inoperable pancreatic cancer: gemcitabine combined with cisplatin versus gemcitabine alone.Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer.Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone.A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses.Gemcitabine versus gemcitabine combined with cisplatin treatment locally advanced or metastatic pancreatic cancer: a retrospective analysis.Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy).Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma.Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.The role of radiotherapy in multimodal treatment of pancreatic carcinoma Current and emerging therapies for the treatment of pancreatic cancer.Pancreatic adenocarcinoma Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer.Chronic pancreatitis and systemic inflammatory response syndrome prevent impact of chemotherapy with gemcitabine in a genetically engineered mouse model of pancreatic cancer.A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma.Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas.Systemic therapy for metastatic pancreatic adenocarcinoma.ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer.Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies.Recent developments in the pharmacological treatment of advanced pancreatic cancer.Docetaxel as salvage therapy in highly pretreated and drug resistant gastrointestinal carcinomas.Advanced pancreatic cancer: is there a role for combination therapy?Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway.Oncolytic virotherapy for pancreatic cancer.Review article: chemotherapy for pancreatic cancer.

P2860

Q24627664-C6AD83C8-AF7E-4B5B-B6FD-9C65883A0EC1 Q24685678-72616E26-9150-4353-AF7B-62E2E40367CE Q26740598-9B47BA79-76BF-4105-A33F-BD8070CD585C Q26828959-936AC59A-24AD-4FB8-A1D8-1FD146A91880 Q26830913-97E86DE3-4EE0-4436-BE5E-17E43DC00D11 Q28484635-78444D67-CA76-4FCC-B449-7D70FD3CA735 Q28487656-F494116B-1A87-4698-AF39-7491460FBB29 Q30355939-0C15A2B6-57C3-40D6-B567-E4D55800C424 Q33265964-CA20CACC-CE8E-4150-8FCA-625C31A369C1 Q33326148-808AE050-5642-47C4-9244-D2FEB7419ACB Q33369923-FD902F9C-E17F-4C5B-AB3E-3A5454C4B54A Q33371225-2E2A1938-F880-45E0-8158-3DF7A800E6FE Q33373308-673CE36F-F717-49B2-967E-62C4AE8C8D3F Q33377668-7F89240B-CCD9-40BB-B0CB-4B6DA781D861 Q33380084-6EC542D9-6E90-4FC9-9708-D4EBC3BF7A50 Q33385864-5EADB2A1-A7FA-46ED-9290-25B2DB5231C2 Q33389637-7997548E-3A78-47C4-939A-8E4B7B424A56 Q33403498-2F880946-BDB8-4791-A1B7-D2DACEAE061F Q33412585-2F09D899-411E-486F-87FA-D9A3385E8538 Q33428016-6A46AC2A-2952-429B-A92E-3B6AA9E7D2A3 Q33430378-2D49F4E3-03E8-4AA0-B795-A8E7077635C2 Q33632330-1A3FE3E9-535C-4ABA-A148-778382C0E71F Q34025910-BAA7E31E-B52A-4CCD-9515-B363E4041F6B Q34129346-B8BF071D-8971-4B3A-A05C-0620193C336E Q34140498-8FB0903F-38F5-4400-9809-153BA302888B Q34257664-5AEE88FF-33EA-4412-94F6-9664904004BA Q34294011-9D3B298F-7E25-446C-AB43-470047392A77 Q34346758-708B118B-CFD2-49AF-A427-976A54BE2C7F Q34750537-71C5E701-41B3-4B31-A954-E3DB1CFC1DBD Q34818494-D9075A1B-EA67-4096-9B02-5EA68EDCFA95 Q35028999-BCCFC9A2-77C9-47D9-8B47-6C08CE27D6BC Q35076238-6A2AD9D2-C751-41E1-90E8-84766373351D Q35098294-B59F511F-85FE-4CF9-B7BF-28D09E504FB7 Q35136815-8A287149-4AEF-45D5-989B-BB13707FD80B Q35144004-422A77E5-215E-4AD9-B57B-7DC2677A876B Q35181089-1744D384-DAC4-40A6-84F8-5E8EBD283ECC Q35576200-407F0FD0-1B5B-46BE-8AC7-1A06222E1B27 Q35578720-D6077C51-11AD-41CA-89CE-AC6D4825795B Q35590996-FD0A374D-1B5E-4825-8753-677CDBFCC122 Q35599597-EF338254-5E7C-4077-A828-264FAF2A7EB8

P2860

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.

Item

http://www.wikidata.org/entity/Q34522003

description

2002 nî lūn-bûn

@nan

2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu